ERBB2 and non-small cell lung carcinoma: In a preclinical study comparing the activity of different TKIs in vitro and in patient-derived xenograft (PDX) models with HER2 exon 20-mutant NSCLC, poziotinib was more effective than other HER2 TKIs.